C4 Therapeutics, Inc. Capital Expenditures
C4 Therapeutics, Inc. (CCCC) reported Capital Expenditures of $101.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-11
- C4 Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $37.00K, a 80.00% decline year-over-year.
- C4 Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $64.00K.
- C4 Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $11.00K.
- C4 Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $411.00K.
- C4 Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $607.00K, a 237.22% increase from fiscal 2024.
- C4 Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $180.00K, a 89.46% decline from fiscal 2023.
- C4 Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $1.71M, a 68.92% decline from fiscal 2022.
- C4 Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $5.50M, a 330.38% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $101.00K 10-Q · filed 2026-08-11 | $112.00K derived: sum of 3 quarters · filed 2026-08-11 | $523.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $64.00K 10-Q · filed 2026-05-12 | $75.00K derived: sum of 2 quarters · filed 2026-05-12 | $486.00K derived: sum of 3 quarters · filed 2026-05-12 | $671.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $422.00K derived: sum of 2 quarters · filed 2026-02-26 | $607.00K derived: sum of 3 quarters · filed 2026-08-11 | $607.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $411.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $596.00K derived: sum of 2 quarters · filed 2026-08-11 | $596.00K 10-Q · filed 2025-11-06 | $592.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $185.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $185.00K 10-Q · filed 2026-08-11 | $181.00K derived: sum of 3 quarters · filed 2026-08-11 | $168.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | -$4.00K derived: sum of 2 quarters · filed 2026-05-12 | -$17.00K derived: sum of 3 quarters · filed 2026-05-12 | $180.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$17.00K derived: sum of 2 quarters · filed 2026-02-26 | $180.00K derived: sum of 3 quarters · filed 2026-02-26 | $180.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $184.00K derived: sum of 2 quarters · filed 2025-11-06 | $184.00K 10-Q · filed 2025-11-06 | $341.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $197.00K 10-Q · filed 2025-08-07 | $354.00K derived: sum of 3 quarters · filed 2025-08-07 | $954.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $157.00K derived: sum of 2 quarters · filed 2025-02-27 | $757.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.12M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | $157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $757.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.12M derived: sum of 3 quarters · filed 2025-02-27 | $1.71M 10-K · filed 2025-02-27 |
| 2023-09-30 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $962.00K derived: sum of 2 quarters · filed 2024-10-31 | $1.55M 10-Q · filed 2024-10-31 | $3.04M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $362.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $951.00K 10-Q · filed 2024-08-01 | $2.44M derived: sum of 3 quarters · filed 2024-08-01 | $5.75M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $589.00K 10-Q · filed 2024-05-08 | $2.08M derived: sum of 2 quarters · filed 2024-05-08 | $5.38M derived: sum of 3 quarters · filed 2024-05-08 | $5.91M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $4.79M derived: sum of 2 quarters · filed 2024-02-22 | $5.32M derived: sum of 3 quarters · filed 2024-02-22 | $5.50M 10-K · filed 2024-02-22 |
| 2022-09-30 | $3.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $3.83M derived: sum of 2 quarters · filed 2023-11-01 | $4.01M 10-Q · filed 2023-11-01 | $4.12M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $529.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $701.00K 10-Q · filed 2023-08-08 | $810.00K derived: sum of 3 quarters · filed 2023-08-08 | $810.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $172.00K 10-Q · filed 2023-05-04 | $281.00K derived: sum of 2 quarters · filed 2023-05-04 | $281.00K derived: sum of 3 quarters · filed 2023-05-04 | $1.03M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $109.00K derived: sum of 2 quarters · filed 2023-02-23 | $856.00K derived: sum of 3 quarters · filed 2023-02-23 | $1.28M 10-K · filed 2023-02-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $747.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.17M 10-Q · filed 2022-11-03 | $1.46M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $747.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.17M 10-Q · filed 2022-08-04 | $1.46M derived: sum of 3 quarters · filed 2022-08-04 | $1.74M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $421.00K 10-Q · filed 2022-05-05 | $712.00K derived: sum of 2 quarters · filed 2022-05-05 | $996.00K derived: sum of 3 quarters · filed 2022-05-05 | $887.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $291.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $575.00K derived: sum of 2 quarters · filed 2022-02-24 | $466.00K derived: sum of 3 quarters · filed 2022-02-24 | $650.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $284.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $175.00K derived: sum of 2 quarters · filed 2021-11-10 | $359.00K 10-Q · filed 2021-11-10 | $286.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$109.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $75.00K 10-Q · filed 2021-08-11 | $2.00K derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | $184.00K 10-Q · filed 2021-05-13 | $111.00K derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | -$73.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.35M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $1.42M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |